Details for Patent: 8,268,349

Which drugs does patent 8,268,349 protect, and when does it expire?

Patent 8,268,349 protects VIEKIRA XR, VIEKIRA PAK (COPACKAGED), and TECHNIVIE, and is included in three NDAs.

Protection for TECHNIVIE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-four patent family members in thirty-seven countries.

Summary for Patent: 8,268,349

Title:	Solid pharmaceutical dosage form
Abstract:	A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s):	Rosenberg; Joerg (Ellerstadt, DE), Reinhold; Ulrich (Heidelberg, DE), Liepold; Bernd (Dossenheim, DE), Berndl; Gunther (Herxheim, DE), Breitenbach; Joerg (Mannheim, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Gurnee, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	13/449,958
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,268,349
Patent Claim Types: see list of patent claims	Dosage form; Formulation; Process;

Drugs Protected by US Patent 8,268,349

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie Inc	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y
Abbvie Inc	VIEKIRA PAK (COPACKAGED)	dasabuvir sodium; ombitasvir, paritaprevir, ritonavir	TABLET;ORAL	206619-001	Dec 19, 2014		DISCN	Yes	No			Y
Abbvie Inc	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y

International Family Members for US Patent 8,268,349

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055734
Argentina	077411
Australia	2006216856